CD19 and precursor B-cell acute lymphoblastic leukemia: The CD19/CD3 BiTE blinatumomab has shown a remarkable anti-tumor efficacy in CD19 positive cells [39], and was approved by the FDA for the treatment of B-cell precursor acute lymphoblastic leukemia (B-ALL) in 2014 [40].